2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]ethanol | 477541-28-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]ethanol
• 英文别名: 2-[5-Methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]ethanol
• CAS: 477541-28-9
• 化学式: C₁₅H₁₉NO₂
• 分子量: 245.321
• InChiKey: MSVIYOOIVHLTEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]ethanol 在 lithium hydroxide 、 三苯基膦 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 2-(5-{2-[2-(4-isopropylphenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy}-2,3-dihydro-1H-inden-1-yl)butanoic acid
  参考文献：
  名称：

  Substituted indanylacetic acids as PPAR-α–γ activators

  摘要：

  A series of oxazole-substituted indanylacetic acids were prepared which show a spectrum of activity as ligands for PPAR nuclear receptor subtypes. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.008
• 作为产物：
  描述：

  methyl 2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]acetate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 2-[2-(4-isopropylphenyl)-5-methyloxazol-4-yl]ethanol
  参考文献：
  名称：

  EP1398313

  摘要：

  公开号：

文献信息

• Novel heterocyclic derivatives and medicinal use thereof
  申请人：——

  公开号：US20040180924A1

  公开（公告）日：2004-09-16

  The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I′) 1 wherein R 1 is a hydrogen atom or C 1-6 alkyl, R 2 is —CO—C(R 4 )═C(R 4 )—R 5 wherein R 4 is a hydrogen atom or C 1-4 alkyl, and R 5 is C 4-8 alkyl, C 2-8 alkenyl, aryl or aromatic heterocycle, —CO—C≡C—R 6 wherein R 6 is C 1-8 alkyl and the like, R 3 is a hydrogen atom or C 1-4 alkyl, X is an oxygen atom or a sulfur atom, R 20 is optionally substituted phenyl, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I′) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases and an agent for the prophylaxis or treatment of syndrome X.

  本发明的新型杂环衍生物是一种具有公式（I'）的新型杂环衍生物，其中R1是氢原子或C1-6烷基，R2是—CO—C(R4)═C(R4)—R5，其中R4是氢原子或C1-4烷基，R5是C4-8烷基、C2-8烯基、芳香族或芳香族杂环，—CO—C≡C—R6，其中R6是C1-8烷基等，R3是氢原子或C1-4烷基，X是氧原子或硫原子，R20是可选取代的苯基，n是1到4的整数，或其药学上可接受的盐。本发明的化合物（I'）可用作降血糖剂、降血脂剂、胰岛素抵抗改善剂、糖尿病治疗剂、糖尿病并发症治疗剂、葡萄糖耐量改善剂、抗动脉硬化剂、抗肥胖剂、抗炎剂、预防或治疗PPAR介导的疾病的药剂和预防或治疗X综合征的药剂。
• NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：EP1398313A1

  公开（公告）日：2004-03-17

  The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I') wherein R1 is a hydrogen atom or C1-6 alkyl, R2 is -CO-C(R4)=C(R4)-R5 wherein R4 is a hydrogen atom or C1-4 alkyl, and R5 is C4-8 alkyl, C2-8 alkenyl, aryl or aromatic heterocycle, -CO-C≡C-R6 wherein R6 is C1-8 alkyl and the like, R3 is a hydrogen atom or C1-4 alkyl, X is an oxygen atom or a sulfur atom, R20 is optionally substituted phenyl, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I') of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases and an agent for the prophylaxis or treatment of syndrome X.

  本发明的新型杂环衍生物是具有式（I'）的新型杂环衍生物 其中 R1 是氢原子或 C1-6 烷基，R2 是 -CO-C(R4)=C(R4)-R5 其中 R4 是氢原子或 C1-4 烷基，R5 是 C4-8 烷基、C2-8 烯基、芳基或芳香杂环，-CO-C≡C-R6 其中 R6 是 C1-8 烷基等，R3 是氢原子或 C1-4 烷基，X 是氧原子或硫原子，R20 是任选取代的苯基，n 是 1 至 4 的整数，或其药学上可接受的盐。本发明的化合物（I'）可用作降血糖剂、降血脂剂、胰岛素抵抗改善剂、糖尿病治疗剂、糖尿病并发症治疗剂、葡萄糖耐量改善剂、抗动脉硬化剂、抗肥胖剂、抗炎剂、预防或治疗 PPAR 介导的疾病的药物以及预防或治疗 X 综合征的药物。
• Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes
  作者：Agnes Bénardeau、Jörg Benz、Alfred Binggeli、Denise Blum、Markus Boehringer、Uwe Grether、Hans Hilpert、Bernd Kuhn、Hans Peter Märki、Markus Meyer、Kurt Püntener、Susanne Raab、Armin Ruf、Daniel Schlatter、Peter Mohr

  DOI：10.1016/j.bmcl.2009.03.036

  日期：2009.5

  Design, synthesis, and SAR of novel alpha-alkoxy-beta-arylpropionic acids as potent and balanced PPARalphagamma coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.
• Indanylacetic acids as PPAR-δ activator insulin sensitizers
  作者：Philip Wickens、Chengzhi Zhang、Xin Ma、Qian Zhao、John Amatruda、William Bullock、Michael Burns、Louis-David Cantin、Chih-Yuan Chuang、Thomas Claus、Miao Dai、Fernando Dela Cruz、David Dickson、Frederick J. Ehrgott、Dongping Fan、Sarah Heald、Martin Hentemann、Christiana I. Iwuagwu、Jeffrey S. Johnson、Ellalahewage Kumarasinghe、David Ladner、Rico Lavoie、Sidney Liang、James N. Livingston、Derek Lowe、Steve Magnuson、Gretchen Mannelly、Ingo Mugge、Herbert Ogutu、Susan Pleasic-Williams、Robert W. Schoenleber、Jeff Shapiro、Tatiana Shelekhin、Laurel Sweet、Christopher Town、Manami Tsutsumi

  DOI：10.1016/j.bmcl.2007.03.057

  日期：2007.8

  A series of indane acetic acid derivatives were prepared which show a spectrum of activity as insulin sensitizers and PPAR-ot and PPAR-delta ligands. In vivo data are presented for insulin sensitizers with selectivity for PPAR-delta over PPAR-Oc. (c) 2007 Published by Elsevier Ltd.
• US6872732B2
  申请人：——

  公开号：US6872732B2

  公开（公告）日：2005-03-29